Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

At Verrica, our mission is to improve the lives of people who suffer from skin diseases by developing innovative, patient-driven therapies based on cutting-edge science.

Our vision is to be a leader in the field of medical dermatology, pushing the boundaries of innovation and utilizing the latest scientific advancements to deliver transformative new treatments for skin diseases.

Verrica has been recognized for its dedication to developing revolutionary therapies for skin diseases. The company has earned recognition from the Dermatology Innovation Council, as well as numerous industry awards for its clinical achievements.